Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 13 of 13 for “"Mantle Cell Lymphoma"”.
-
The Biology of Mantle Cell Lymphoma: Exploring the Gender Difference in Mantle Cell Lymphoma
Mantle cell lymphoma (MCL) is a rare B cell neoplasm that accounts for approximately 4-8% of non-Hodgkin’s lymphomas (NHLs). The median age at diagnosis is 65 years with a male to female predominance of 3:1. It has also been demonstrated that female MCL patients have a greater response to therapy, …
-
Targeted therapies in mantle cell lymphoma
Mantle cell lymphoma (MCL) is characterized by the presence of the t(11 ;14)(g13 ;g32) translocation which results in cyclin Dl over-expression. MCL is one of the most difficult lymphoproliferative disorders to manage with a median survival rate of 43 months from diagnosis. The poor prognosis …
-
Type I Insulin-Like Growth Factor Receptor Tyrosine Kinase As A Molecular Target In Mantle Cell Lymphoma
Mantle cell lymphoma (MCL) is an aggressive B-cell lymphoid malignancy representing 5-10% of all non-Hodgkin’s lymphomas. It is distinguished by the t(11;14)(q13;q32) chromosomal translocation that juxtaposes the proto-oncogene CCND1, which encodes cyclin D1 at 11q13 to the IgH gene at 14q32. MCL …
-
Exploring the role of IRF4 in the sensitivity of mantle cell lymphoma cells to Bruton's Tyrosine Kinase inhibitors
Introduction and aim: Mantle cell lymphoma (MCL) is an aggressive subtype of B-cell lymphoma. Therapy using Bruton’s tyrosine kinase (BTK) inhibitors has improved clinical outcomes but primary and secondary resistance to BTK inhibitor (BTKi) therapy affects more than half of MCL patients. …
-
Role of Manganese Superoxide Dismutase in Chemotherapy-induced Oxidative Stress
Existing treatments for mantle cell lymphoma (MCL) are non-curative, demonstrating a need for a refined treatment approach. Recent clinical trials have shown promising results with the use of mammalian target of rapamycin inhibitors. I hypothesize that the anti-tumor effect of mTOR inhibitors in …
-
Differential Pax5 Levels Promote Mcl Dispersal and Progression and Predict A Poor Prognosis In Advanced Mcl Patients
… silencing in mice models led to aggressive lymphoma formation, there has been a lack of understanding in the precise functions of PAX5 in human B cell cancers. PAX5 expression is used to diagnose different B cell lymphoma in the clinic including mantle cell lymphoma (MCL), which is one of …
-
Biochemical and computational studies towards selective inhibition of the immunoproteasome
… influencing key regulatory pathways including: cell cycle control, DNA repair and apoptosis. As such, proteasome inhibitors (PI) have exhibited broad therapeutic applications, particularly for multiple myeloma and mantle cell lymphoma with 3 inhibitors gaining FDA approval. However, covalent …
-
Nutlin-3 sensitizes cancer cells to bortezomib via induction of paraptosis-associated cell death
… 80-90% of proteins, and is central to regulating cellular function and keeping protein homeostasis. Since proteasome inhibition can lead to the accumulation of the misfolded proteins and subsequent proteotoxicity in tumor cells, the proteasome is considered a target for cancer therapies. …
-
Co-optation of B Cell Developmental States in Malignancy and Autoimmunity
… a useful lens for understanding the diversity of cell identity and function. Cell state is regulated through both cell-intrinsic and -extrinsic mechanisms, and can diversify through tightly regulated transitions. However, perturbations to these regulatory mechanisms facilitate shifts in cell …
-
Pim Kinase Inhibition: Single Agent and Combination Approaches In B-Cell Lymphoma
… kinases are Ser/Thr/Tyr kinases. They modulate B-cell development but become oncoproteins and promote cancer development once overexpressed. Containing three isoforms, Pim-1, -2 and -3 are known to phosphorylate various substrates that regulate transcription, translation, cell cycle, and survival …
-
Potentiating Antibody Therapy by Targeting Complement on Cancer Cells
… but mAb-induced antigen loss on tumor cells can lead to treatment failure. Loss of cell surface CD20 can occur in the treatment of lymphoid malignancies with anti-CD20 antibodies (mAbs) (eg rituximab, ofatumumab) through trogocytosis. This is a frustrated form of phagocytosis, where the …
-
Klinische Bedeutung von immunhistochemischen und zytogenetischen Risikofaktoren beim Mantelzell-Lymphom
… mit den Ergebnissen von Rosenwald et al. (Cancer cell, 2/2003, Vol. 3, Seiten 185-197) konnten wir zeigen, daß der Proliferationsindex auch dann mit der Überlebensdauer korreliert ist, wenn man vier Gruppen mit ansteigendem Proliferationsindex (PI) bildet. Dies beweist die Bedeutung des PI bei …
-
Novel approaches to assess cellular interactions and their role in the pathology and treatment of lymphoproliferative disorders
… cytoskeletal alterations mediated by B-cell receptor (BCR) engagement or chemokine-binding are recognised to be central to the migration of CLL cells to lymphoid tissues, where they engage in the complex cellular and molecular interactions that underlie their survival, proliferation, and …